INmune Bio licenses MissionEB data, plans BLA for CORDStrom in pediatric RDEB

Inmune Bio, Inc.

Plans to submit BLA in 2025 for CORDStrom to treat pediatric RDEB, supported by positive Phase 2 MissionEB data in 30 patients.
Licensed exclusive commercial rights to MissionEB data from Great Ormond Street Hospital for £250k upfront and up to £6M milestone on first marketing authorization.
FDA granted Rare Pediatric Disease Designation (RPDD) Dec 2024 and Orphan Drug Designation (ODD) Jan 2025, preserving PRV eligibility.
CORDStrom well tolerated; severe RDEB patients had >27% sustained itch reduction at 6 months; younger and intermediate patients showed skin and pain improvements.
Terminated existing SVB loan agreement with zero balance and no penalty; no financial impact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.